NASDAQ:EQ
Equillium, Inc.
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
equilliumbio.comipo date
Oct 12, 2018
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials fo...Show More
Earnings
Earnings Release in 11 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus